Related Experiment Video
Updated: Feb 22, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
A Robert MacLeod1, Stanley T Crooke2
1Vice President, Oncology Discovery, Ionis Pharmaceuticals, Carlsbad, CA, USA.
Abstract:
RNA-based therapeutic technologies represent a rapidly expanding class of therapeutic opportunities with the power to modulate cellular biology in ways never before possible. With RNA-targeted therapeutics, inhibitors of previously undruggable proteins, gene expression modulators, and even therapeutic proteins can be rationally designed based on sequence information alone, something that is not possible with other therapeutic modalities. The most advanced RNA therapeutic modalities are antisense oligonucleotides (ASOs) and small interfering RNAs. Particularly with ASOs, recent clinical data have demonstrated proof of mechanism and clinical benefit with these approaches across several nononcology disease areas by multiple routes of administration. In cancer, next-generation ASOs have recently demonstrated single-agent activity in patients with highly refractory cancers. Here we discuss advances in RNA therapeutics for the treatment of cancer and the challenges that remain to solidify these as mainstay therapeutic modalities to bridge the pharmacogenomic divide that remains in cancer drug discovery.
Insights
RNA therapeutics, including antisense oligonucleotides (ASOs), offer novel ways to target diseases. Recent advances show promise in treating refractory cancers, highlighting their potential in cancer drug discovery.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- RNA-based therapeutics offer unprecedented control over cellular processes.
- RNA-targeted drugs can address previously undruggable targets.
- Antisense oligonucleotides (ASOs) and small interfering RNAs are leading RNA therapeutic modalities.
Purpose of the Study:
- To review advances in RNA therapeutics for cancer treatment.
- To discuss the potential of RNA therapeutics in bridging the pharmacogenomic divide in cancer drug discovery.
- To highlight challenges in establishing RNA therapeutics as a mainstream cancer treatment.
Main Methods:
- Review of recent clinical data on RNA therapeutics, particularly ASOs.
- Discussion of next-generation ASOs demonstrating single-agent activity in refractory cancers.
- Analysis of sequence-based rational design for RNA-targeted therapeutics.
Main Results:
- ASOs have shown proof of mechanism and clinical benefit in nononcology diseases via multiple administration routes.
- Next-generation ASOs exhibit single-agent activity in highly refractory cancer patients.
- RNA therapeutics enable rational drug design based on sequence information.
Conclusions:
- RNA therapeutics, especially ASOs, are emerging as powerful tools in oncology.
- Further development is needed to establish RNA therapeutics as a mainstay in cancer treatment.
- RNA-based approaches hold significant potential for personalized cancer medicine.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Microorganisms in Medicine and Therapeutics
02:18Cancer
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...